ReviewThe American journal of the medical sciences2022
COVID-19 and the cardiovascular system: an update.
Review in The American journal of the medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Angiographic and Electrocardiographic Characteristics of Patients With Non-ST-Segment Elevation Myocardial Infarction and COVID-19.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- The impact of post-acute sequelae of COVID-19 on cardiac function and structure: A systematic review and a hybrid individual participant data meta-analysis.American journal of preventive cardiology · 2026Review
- The Impact of the COVID-19 Pandemic on Iodine Nutrition Status of Pregnant Women and Infants/Toddlers: Repeated Cross-Sectional Studies in Zhengzhou, China.Biological trace element research · 2026Article
- Ischaemic heart disease is the factor associated with severe COVID-19 in the urban population of Uzbekistan: a single‑center retrospective study.BMC infectious diseases · 2026Article
- Risk assessment for cardiovascular adverse drug events in the ICU: Case study on COVID-19 patients.PloS one · 2026Article
- Carrying APOL1 G1 allele is associated with cardiovascular complications during COVID-19 in an admixed population.Human genomics · 2025Article
- Effectiveness and safety of azvudine versus nirmatrelvir/ritonavir in hospitalized patients with COVID-19.BMC infectious diseases · 2025Article
- Novel idebenone derivatives attenuated oxidative stress injury and myocardial damage.Frontiers in chemistry · 2025Article
- Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.Journal of cellular physiology · 2024Review
- Development and validation of nomogram models for severe and fatal COVID-19.Scientific reports · 2024Article
- Perioperative cardiovascular risk and preventions of patients with post-COVID-19 condition.Heliyon · 2024Review
- Cardiovascular Comorbidities in COVID-19: Comprehensive Analysis of Key Topics.Interactive journal of medical research · 2024Article
- Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID.NPJ science of food · 2024Review
- The COVID-19 inflammation and high mortality mechanism trigger.Immunogenetics · 2024Review
- Association of COVID-19 and Arterial Stiffness Assessed using Cardiovascular Index (CAVI).Current hypertension reviews · 2024Article
- Factors influencing cardiovascular system-related post-COVID-19 sequelae: A single-center cohort study.Open medicine (Warsaw, Poland) · 2024Article
- Effects of COVID-19 on bone fragility: a new perspective from osteoimmunological biomarkers.Frontiers in immunology · 2024Article
- Clinical indications and outcomes of Impella devices for severe cardiogenic shock in COVID-19 patients: a systematic review.Annals of medicine and surgery (2012) · 2023Review
- Article
- Comparative Study of the Myocardium of Patients from Four COVID-19 Waves.Diagnostics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As COVID-19 continues to cause an increasing number of deaths worldwide, it is important that providers stay abreast with new research related to the pathophysiology of COVID-19 disease presentation states and clinical management. It is now well recognized that COVID-19 affects extrapulmonary organs, particularly the cardiovascular system. For example, cardiogenic shock has been increasingly observed in patients with COVID-19, owing to the various mechanisms involved and the affinity of the SARS-CoV-2 virus to cells comprising the cardiovascular system. In this review, we have briefly discussed the link between the cardiovascular system and COVID-19 infection, focusing on underlying mechanisms including but not limited to cytokine storm, direct virus-induced myocarditis, and ST-elevation myocardial infarction leading to cardiogenic shock. We have highlighted the cardiovascular risk factors associated with disease prognostication in COVID-19 patients. We have also briefly discussed vasopressors and inotropes used for treating shock and presented their mechanism of action, contraindications, and side effects in the hopes of providing a quick reference to help the provider optimize management of COVID-19 patients presenting with cardiovascular complications such as shock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.